Hermetica Superfood Encyclopedia
The Short Answer
Rewarewa honey contains arabinogalactan proteins (AGPs), diacyl compounds, and polyphenols including quinic acid, which inhibit neutrophil superoxide production (IC50 4.3 mg/ml) and suppress leukocyte-mediated inflammation. Topical application in a mouse ear oedema model abrogated arachidonic acid-induced swelling and neutrophil infiltration at levels comparable to mānuka honey, representing the strongest preclinical evidence available for this ingredient.
CategoryHerb
GroupPacific Islands
Evidence LevelPreliminary
Primary Keywordrewarewa honey benefits
Rewarewa — botanical close-up
Health Benefits
**Anti-inflammatory Activity**
Rewarewa honey inhibits neutrophil superoxide production in vitro at an IC50 of 4.3 mg/ml and reduces ear oedema and leukocyte infiltration in vivo in mouse models, with diacyl compounds proposed as the primary active contributors.
**Antibacterial Properties**
At 25% concentration, rewarewa honey demonstrates antibacterial activity against a range of bacteria, attributed to arabinogalactan proteins (AGPs) and polyphenolic constituents rather than hydrogen peroxide or methylglyoxal pathways.
**Antioxidant Capacity**
Polyphenolic compounds in rewarewa honey produce measurable antioxidant activity across multiple assays (CUPRAC 0.244, FRAP 0.320, DPPH 0.155 at 12.50% concentration), indicating moderate free radical scavenging capability.
**Respiratory Support (Traditional)**
Māori healers traditionally used leaves of Knightia excelsa to relieve coughing, representing one of the earliest documented therapeutic applications of this plant within indigenous Aotearoa medicine.
**Neutrophil Modulation**
Beyond simple antioxidant action, rewarewa honey appears to interfere with neutrophil activation pathways independently of direct reactive oxygen species quenching, suggesting a receptor-level or signalling-mediated mechanism relevant to inflammatory disease management.
**Polyphenol Delivery**
Rewarewa honey-derived food products such as ice cream contain significantly high concentrations of quinic acid, a bioactive polyphenol with documented antioxidant and potential neuroprotective properties, indicating the honey as a functional polyphenol source.
Origin & History
Natural habitat
Knightia excelsa is an endemic New Zealand tree belonging to the Proteaceae family, growing naturally throughout the North Island and upper South Island of Aotearoa New Zealand in lowland and montane forests. It thrives in well-drained, moderately fertile soils and is one of the few members of the Proteaceae family native to New Zealand, reaching heights of up to 30 metres. The tree produces distinctive crimson tubular flowers that are a rich nectar source for native birds such as tūī and kererū, and these flowers are also harvested by bees to produce the monofloral honey that has become the primary subject of modern scientific investigation.
“Knightia excelsa holds significance in Māori traditional medicine (rongoā Māori), where the leaves were used to relieve coughing, representing one of the documented applications of this endemic tree in indigenous health practice in Aotearoa New Zealand. The tree's Māori name 'rewarewa' is well established in New Zealand botanical and cultural lexicons, and the species is considered taonga (treasured) as part of the native forest ecosystem that Māori communities have long managed and inhabited. The crimson flowers of rewarewa attracted native birds central to Māori ecological and cultural life, and the tree's honey-producing capacity — exploited by introduced European honeybees — has given it renewed contemporary significance as a premium New Zealand monofloral honey. Detailed historical records of specific preparation methods, ceremonial use, or broader pharmacopoeia classification within rongoā Māori are limited in currently available literature, underscoring the need for deeper ethnobotanical documentation in collaboration with iwi knowledge holders.”Traditional Medicine
Scientific Research
The available scientific evidence for rewarewa (Knightia excelsa) and its honey is limited exclusively to in vitro and in vivo preclinical studies; no human clinical trials have been conducted or registered as of current available data. Key in vitro findings include neutrophil superoxide inhibition with an IC50 of 4.3 mg/ml from a single honey sample (n=1 sample), which falls within the range reported for mānuka and kānuka honeys (3.1–6.1 mg/ml), providing a useful but preliminary benchmark. In vivo evidence derives from topical application experiments in C57BL/6J mice using arachidonic acid-induced ear inflammation, where rewarewa honey (designated H21) significantly abrogated oedema and leukocyte infiltration, with results comparable to mānuka honey (H10), though specific animal group sizes were not reported in available summaries. Antioxidant profiling across multiple validated assay systems (CUPRAC, FRAP, DPPH, TFC, TPC) places rewarewa honey at an intermediate position among New Zealand monofloral honeys, providing consistent physicochemical characterisation but no clinical outcome data.
Preparation & Dosage
Traditional preparation
**Raw Monofloral Honey (Oral)**
5–10 ml) for throat and cough relief, consistent with Māori use of the plant for coughing
No clinically established dose; traditional and anecdotal use follows general honey conventions of 1–2 teaspoons (.
**Topical Honey Application**
Preclinical mouse studies applied honey directly to tissue surfaces; no standardised human topical dose or formulation protocol has been established.
**In Vitro Reference Concentrations**
3 mg/ml — these are laboratory reference points, not supplement dosing guidelines
Antibacterial activity observed at 25% w/v; antioxidant profiling conducted at 12.50% concentration; neutrophil inhibition IC50 determined at 4..
**Traditional Leaf Preparation**
Māori traditional use involved leaves of Knightia excelsa for cough relief; specific preparation method (infusion, decoction, or direct application) is not documented in available ethnobotanical records.
**Standardised Extracts or Capsules**
No commercially standardised extracts, capsules, or tinctures of rewarewa leaf or honey are currently available; the honey is consumed as a whole food product rather than a concentrated supplement.
Nutritional Profile
Rewarewa honey, as a food product, shares the general macronutrient profile of honey — predominantly simple sugars (fructose and glucose comprising approximately 65–80% of dry weight) with negligible protein and fat content. Its most pharmacologically relevant constituents are polyphenols, with quinic acid present at significantly elevated concentrations in rewarewa honey-derived products, alongside a broader polyphenolic pool contributing to a total phenolic content (TPC) of 1.853 (units at 12.50% concentration in standardised assay). Arabinogalactan proteins (AGPs) are detected at moderate levels, lower than those found in kānuka, kāmahi, pōhutukawa, and mānuka honeys, and these glycoproteins contribute to both viscosity and biological activity. Methylglyoxal (MGO), the principal antibacterial compound in mānuka honey, is absent or undetectable (0 mg/kg) in rewarewa honey, distinguishing its antibacterial mechanism as polyphenol- and AGP-dependent rather than MGO-dependent; bioavailability of honey polyphenols is generally considered moderate and influenced by gut microbiome composition.
How It Works
Mechanism of Action
Rewarewa honey inhibits neutrophil superoxide production independently of direct free radical scavenging and independently of xanthine/xanthine oxidase-derived superoxide, indicating that its anti-inflammatory action targets neutrophil activation signalling rather than acting as a simple antioxidant. The diacyl compounds present at high concentrations in rewarewa honey are proposed as the candidate molecules responsible for this effect, potentially interfering with NADPH oxidase assembly or upstream neutrophil priming pathways, though precise receptor or enzyme targets have not yet been characterised. In vivo, topical rewarewa honey reduces leukocyte infiltration and tissue oedema in arachidonic acid-challenged mouse ears, with the primary cellular effect being suppression of neutrophil influx; this is hypothesised to occur via modulation of resident tissue cell signalling or inhibition of neutrophil self-recruitment chemotactic loops. Arabinogalactan proteins (AGPs), detected at moderate levels in rewarewa honey, may contribute to antibacterial activity through disruption of bacterial cell surface interactions, a mechanism increasingly documented for AGP-rich honeys.
Clinical Evidence
No human clinical trials have been completed for rewarewa honey or Knightia excelsa plant extracts in any therapeutic indication, meaning all clinical inferences must be drawn cautiously from preclinical models. The most robust preclinical data concerns topical anti-inflammatory efficacy in a validated mouse ear oedema model, where rewarewa honey abrogated arachidonic acid-induced inflammation with potency comparable to mānuka honey, which itself has a broader but still limited clinical evidence base. In vitro antibacterial testing at 25% concentration and neutrophil superoxide suppression (IC50 4.3 mg/ml) provide supportive mechanistic data, but effect sizes in human tissues and therapeutic dose equivalents cannot be extrapolated without controlled human studies. Overall confidence in clinical benefit is low due to the absence of randomised controlled trials, standardised extract preparations, defined dose ranges, and pharmacokinetic data in humans.
Safety & Interactions
No adverse effects, drug interactions, or contraindications specific to rewarewa honey or Knightia excelsa plant extracts have been reported in the scientific literature, and mouse topical application studies noted no observed toxicity. Standard honey contraindications apply: rewarewa honey should not be administered to infants under 12 months due to the universal risk of Clostridium botulinum spore germination in the immature gut microbiome. Individuals with known bee-product allergies (including pollen or propolis sensitivities) should exercise caution with any monofloral honey, including rewarewa, as allergenic proteins from floral sources may be present. No formal toxicology studies, maximum tolerated dose data, reproductive toxicity assessments, or drug interaction evaluations exist for rewarewa honey or plant extracts, meaning safety in pregnancy, lactation, paediatrics, and polypharmacy contexts cannot be formally characterised beyond general honey guidance.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
rewarewa treerewa-rewaMaori Rewarewa (Knightia excelsa)Knightia excelsaNew Zealand honeysuckle
Frequently Asked Questions
What is rewarewa honey and how is it different from mānuka honey?
Rewarewa honey is a monofloral honey produced by bees foraging on the flowers of Knightia excelsa, an endemic New Zealand tree. Unlike mānuka honey, rewarewa honey contains no detectable methylglyoxal (0 mg/kg), meaning its antibacterial and anti-inflammatory properties are attributed to arabinogalactan proteins (AGPs) and polyphenolic compounds including quinic acid rather than the MGO pathway that defines mānuka's grading system.
Does rewarewa honey have proven anti-inflammatory effects?
Preclinical evidence supports anti-inflammatory activity: rewarewa honey inhibits neutrophil superoxide production in vitro at an IC50 of 4.3 mg/ml and abrogated arachidonic acid-induced ear oedema and leukocyte infiltration in mice when applied topically. However, no human clinical trials have been conducted, so translating these results to therapeutic recommendations for humans is not yet scientifically justified.
How did Māori traditionally use the rewarewa plant?
In rongoā Māori (Māori traditional medicine), the leaves of Knightia excelsa were used to relieve coughing, making it one of the documented respiratory applications within New Zealand's indigenous herbal tradition. Specific preparation methods — such as whether leaves were brewed as a decoction, infusion, or used in another form — are not detailed in currently available ethnobotanical records.
Is rewarewa honey safe to consume?
Rewarewa honey is considered safe for general adult consumption based on traditional use and the absence of reported adverse effects in available scientific literature. As with all honeys, it must not be given to infants under 12 months due to the risk of infant botulism, and individuals with bee-product or pollen allergies should use caution, as no formal allergy profiling specific to rewarewa honey has been published.
What antioxidant activity does rewarewa honey have compared to other New Zealand honeys?
Rewarewa honey shows intermediate antioxidant activity among New Zealand monofloral honeys, with standardised assay scores of CUPRAC 0.244, FRAP 0.320, and DPPH 0.155 at 12.50% concentration. It ranks below kānuka, kāmahi, and pōhutukawa honeys in arabinogalactan protein levels, but notably contains quinic acid at significantly elevated concentrations, which may contribute to its distinct polyphenolic antioxidant profile.
What is the recommended daily dosage of rewarewa honey for anti-inflammatory benefits?
Clinical studies on rewarewa honey have primarily used concentrations of 25% or higher in laboratory settings, though optimal human dosing has not been formally established through clinical trials. Traditional use and anecdotal reports suggest 1–2 teaspoons daily, but individual tolerance and therapeutic goals should guide consumption. Consult a healthcare provider to determine the appropriate dose for your specific health needs, as rewarewa honey is typically used as a functional food rather than a standardized pharmaceutical dose.
Does rewarewa honey interact with antibiotics or anti-inflammatory medications?
Limited evidence exists on direct pharmacokinetic interactions between rewarewa honey and common medications, though its antibacterial and anti-inflammatory properties warrant caution when combined with antibiotic or immunosuppressant therapies. The diacyl compounds in rewarewa honey that contribute to its bioactivity may theoretically potentiate or compete with certain drug mechanisms, particularly those affecting immune function. Anyone taking prescription medications should consult their healthcare provider before using rewarewa honey therapeutically to avoid unintended interactions.
Is rewarewa honey safe for children or during pregnancy?
Rewarewa honey, like all honey, carries a theoretical risk of botulism in infants under 12 months old and should not be given to this age group. Safety data in pregnant women and nursing mothers is limited, and it is advisable to consult a healthcare provider before use during pregnancy or lactation. For children over one year old, rewarewa honey is generally recognized as safe in typical food quantities, though individual allergies to bee products should be considered.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w rewarewa-knightia-excelsa curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
